Company profile: Convelo Therapeutics
1.1 - Company Overview
Company description
- Provider of novel remyelinating therapeutics that regenerate myelin in the central nervous system to restore function, supported by a proprietary screening platform that identifies candidates acting on oligodendrocyte progenitor cells, and a collaboration with Genentech to accelerate discovery and development of medicines for neurological disorders such as multiple sclerosis.
Products and services
- Novel Remyelinating Therapeutics: Convelo engineers a novel class of CNS-targeted medicines that regenerate myelin around nerve cells to restore function and treat multiple sclerosis, focusing on remyelination within the central nervous system
- Collaboration with Genentech: Convelo delivers an R&D-focused partnership with Genentech to accelerate discovery and development of novel remyelinating medicines for neurological disorders such as multiple sclerosis
- Proprietary Screening Platform: Convelo architects an OPC-directed platform that identifies drug candidates stimulating new myelin formation by directly acting on oligodendrocyte progenitor cells, enabling targeted remyelination mechanisms relevant to multiple sclerosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Convelo Therapeutics
Axsome Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurological disorders, including Auvelity for major depressive disorder and Sunosi to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy; developing AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for acute migraine, and AXS-12 for narcolepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axsome Therapeutics company profile →
NKGen Biotech
HQ: United States
Website
- Description: Provider of natural killer (NK) cell therapy candidates to restore immune function for cancer treatment, including SNK01, an autologous NK therapy in clinical trials for neurodegenerative diseases and various cancers, and SNK02, an allogeneic NK therapy being tested for solid tumors, plus an Expanded Access Program enabling access to investigational therapies under specific conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NKGen Biotech company profile →
Arvelle Therapeutics
HQ: Switzerland
Website
- Description: Provider of innovative biopharmaceutical solutions for patients suffering from central nervous system (CNS) disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arvelle Therapeutics company profile →
Neuros Medical
HQ: United States
Website
- Description: Provider of neurostimulation therapies for patients with unmet medical needs, including the Altius System, a device designed to alleviate chronic post-amputation pain using bioelectric nerve block technology targeting sensory nerves; a patented on-demand high-frequency bioelectric nerve block to block pain signals in sensory nerves; and the QUEST Study, a clinical trial evaluating the safety and effectiveness of the Altius System for treating intractable post-amputation pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuros Medical company profile →
Prestwick Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic pharmaceutical drugs for chronic central nervous system diseases, offering products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea. Founded in 2002 and based in Washington, District of Columbia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prestwick Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Convelo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Convelo Therapeutics
2.2 - Growth funds investing in similar companies to Convelo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Convelo Therapeutics
4.2 - Public trading comparable groups for Convelo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →